Recognizing that much work is needed to completely characterize the function of specific BMPs in liver fibrosis associated with chronic liver injury of different aetiology, evidence gathered in this review could support approaches aimed at blocking BMP2/4 and BMP9 signalling or enhancing BMP7 and BMP6 (in NAFLD-associated fibrosis) as potential strategies that would ultimately lead to decrease the fibrotic process in the liver. This evidence concerns the gene BMP2 and metabolic dysfunction-associated steatotic liver disease.